BridgeBio Pharma, Inc. (BBIO) Dividend History

Company News

• Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk

  Alnylam Pharmaceuticals reported a Q1 2025 earnings beat and affirmed its FY2025 sales guidance. Analysts highlighted the strong launch potential of Amvuttra and limited tariff risk due to the company's U.S.-based manufacturing and IP.

  Benzinga

  Featured Companies: ALNY
• BEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM

  BridgeBio's BEYONTTRA, a near-complete transthyretin stabilizer, has been approved by the UK regulatory agency for the treatment of ATTR-CM, a progressive and fatal heart disease. The approval is based on positive Phase 3 study results, showing significant improvements in cardiovascular outcomes.

  GlobeNewswire Inc.
• Is High-Yield Pfizer Stock Still a Buy After Scrapping Its Weight-Loss Pill?

  Pfizer discontinued development of an experimental weight-management pill, highlighting the risks of drug development. The company also faces upcoming patent expirations for key products and a potential slowdown in FDA approvals due to staffing changes at the agency.

  The Motley Fool

  Featured Companies: ALNY BMY PFE
• BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

  BridgeBio Pharma, a biopharmaceutical company focused on genetic diseases, announced equity grants to 10 new employees in the form of restricted stock units.

  GlobeNewswire Inc.
• BridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt

  BridgeBio Pharma announced the pricing of $500 million in convertible senior notes due 2031. The company plans to use the proceeds to repay existing debt and repurchase shares, which will lower interest expense and provide greater operational flexibility.

  GlobeNewswire Inc.